INSIGHTEC raises $150 million for medical technology focused on Parkinson’s, other diseases
Summary
INSIGHTEC, a commercial-stage medical technology company led by Maurice R. Ferré, announced on Friday that it has raised a Series F investment round of up to $150 million at a post-money valuation of $1.3 billion. “Our partnership with KDT and other investors is helping to fuel our momentum as a rapidly growing number of medical institutions adopt our focused ultrasound technology,” said Ferré, CEO and chairman, in a statement. “This new investment demonstrates our investors’ commitment to help drive the next generation of focused ultrasound.” INSIGHTEC’s Exablate Neuro incisionless neurosurgery platform is approved by the FDA to treat patients suffering from essential tremor and tremor-dominant Parkinson’s disease who have not responded to medications, the company said in its announcement. “KDT is focused on empowering innovative companies and helping them realize their potential to improve the lives of millions of people.” INSIGHTEC was founded in 1999 in Israel. VTI became the world leader in image guided surgery for ENT, cranial and orthopedic procedures and was acquired by GE Healthcare in 2002.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
